Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desvenlafaxine - Pfizer

Next Previous
Drug Profile

Desvenlafaxine - Pfizer

Alternative Names: Desvenlafaxine hydrochloride; Desvenlafaxine SR; Desvenlafaxine succinate; Desvenlafaxine succinate sustained release; Desvenlafaxine sustained-release; Desvenlaflaxine extended release; DVS-233; DVS-233 SR; DVS-SR; MD-120; O-desmethylvenlafaxine; Pristiq; WY-45233

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Jiangsu Hansoh Pharmaceutical; Pfizer; Wyeth
  • Class Amines; Antidepressants; Cyclohexanols; Dimethylamines; Ethylamines; Phenols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Vasomotor symptoms
  • Discontinued Fibromyalgia; Neuropathic pain

Most Recent Events

  • 14 Sep 2022 Mochida Pharmaceutical and Pfizer completes the phase III trial in Major depressive disorders in Japan (PO) (NCT04345471)
  • 12 May 2020 Mochida Pharmaceutical and Pfizer initiated a phase III trial in Major depressive disorders in Japan (PO) before May 2020 (NCT04345471)
  • 17 Apr 2020 Mochida Pharmaceutical in collaboration with Pfizer plans a phase III trial for Major Depressive Disorder in Japan (PO) (NCT04345471)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top